Regenxbio (RGNX) Other Non-Current Liabilities (2018 - 2026)
Regenxbio (RGNX) posted quarterly Other Non-Current Liabilities of $638000.0 for Q4 2025, down 82.45% year-over-year from $3.6 million in Q4 2024, and down 1.54% quarter-over-quarter from $648000.0 in Q3 2025.
Regenxbio (RGNX) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Regenxbio's Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $638000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 82.45% year-over-year to $638000.0; the TTM figure through Dec 2025 stood at $638000.0 (down 82.45% YoY), while the FY2025 annual figure was $638000.0, down 82.45% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $638000.0, down from $648000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $171.3 million in Q4 2021, with the low at $448000.0 in Q1 2021.
- The 5-year median for Other Non-Current Liabilities is $6.9 million (2022), against an average of $37.5 million.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Liabilities surged 26379.82% in 2021, then tumbled 98.15% in 2025.
- Regenxbio's Other Non-Current Liabilities stood at $171.3 million in 2021, then slipped by 19.69% to $137.6 million in 2022, then plunged by 68.4% to $43.5 million in 2023, then slumped by 91.64% to $3.6 million in 2024, then plunged by 82.45% to $638000.0 in 2025.
- Business Quant data shows RGNX's Other Non-Current Liabilities at $638000.0 in Q4 2025, $648000.0 in Q3 2025, and $664000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 486,000.00 |
| Dec 31, 2025 | 638,000.00 |
| Sep 30, 2025 | 648,000.00 |
| Jun 30, 2025 | 664,000.00 |
| Mar 31, 2025 | 11.12 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 35.05 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | 3.49 Mn |
| Dec 31, 2023 | 43.49 Mn |
| Sep 30, 2023 | 6.19 Mn |
| Jun 30, 2023 | 6.08 Mn |
| Mar 31, 2023 | 5.98 Mn |
| Dec 31, 2022 | 137.61 Mn |
| Sep 30, 2022 | 8.66 Mn |
| Jun 30, 2022 | 8.53 Mn |
| Mar 31, 2022 | 7.68 Mn |
| Dec 31, 2021 | 171.35 Mn |
| Sep 30, 2021 | 144.32 Mn |
| Jun 30, 2021 | 151.08 Mn |